Swiss National Bank Buys 28,500 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Swiss National Bank increased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 6.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 458,400 shares of the biotechnology company's stock after buying an additional 28,500 shares during the period. Swiss National Bank owned 0.19% of ADMA Biologics worth $7,862,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ADMA. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of ADMA Biologics during the third quarter worth about $61,858,000. Raymond James Financial Inc. acquired a new position in shares of ADMA Biologics in the fourth quarter valued at approximately $19,076,000. EWG Elevate Inc. bought a new position in ADMA Biologics during the 4th quarter worth about $480,000. Finally, Citigroup Inc. raised its position in ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after buying an additional 277,138 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded down $0.52 during midday trading on Wednesday, hitting $19.70. 2,179,730 shares of the company's stock were exchanged, compared to its average volume of 3,358,824. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.66 billion, a PE ratio of 70.36 and a beta of 0.60. ADMA Biologics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.64. The company's 50 day moving average price is $16.91 and its 200 day moving average price is $18.10.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.